BiotechTube
Cutanos

Cutanos

Vienna, Austria· Est.
cutanos.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $1.5M

Overview

Cutanos is a private, preclinical-stage biotech founded in 2020 in Vienna, Austria, focused on a first-of-its-kind targeted delivery platform for mRNA therapeutics. Its proprietary Langerhans Cell Targeted Delivery System (LC-TDS) utilizes a ligand to specifically target a key subset of skin-resident dendritic cells, aiming to enhance vaccine efficacy while reducing doses and side effects. The company is leveraging its modular platform to develop next-generation vaccines and is supported by Austrian public funding agencies and experienced biotech advisors. Cutanos operates as a platform company, positioning its technology for applications in infectious diseases, oncology, and potentially autoimmune disorders.

OncologyInfectious DiseasesAutoimmune Diseases

Technology Platform

Langerhans Cell Targeted Delivery System (LC-TDS): A ligand-based platform that functionalizes lipid nanoparticles (LNPs) to specifically target and deliver mRNA payloads to Langerhans cells in the skin for precision immune modulation.

Funding History

1
Total raised:$1.5M
Seed$1.5M

Opportunities

The validated mRNA/LNP market creates a massive opportunity for superior, targeted delivery systems.
Cutanos's first-in-class Langerhans cell focus positions it to develop more potent and safer next-generation vaccines for oncology and infectious diseases, with a long-term blue-sky opportunity in antigen-specific tolerance for autoimmune disorders.
The modular platform is highly attractive for potential partnerships with large mRNA and vaccine developers.

Risk Factors

The company faces high technical risk in translating its novel platform from promising preclinical data to human efficacy and safety.
As a pre-revenue startup, it is dependent on securing significant venture capital financing to advance.
It also operates in a fiercely competitive landscape of next-generation LNP targeting technologies.

Competitive Landscape

Cutanos competes in the rapidly advancing field of targeted nucleic acid delivery. Numerous biotechs and large pharma are developing cell-specific LNP targeting technologies using various ligands (antibodies, peptides, sugars). Cutanos's key differentiator is its specific focus on Langerhans cells via a small molecule ligand, a niche not widely addressed, but it must prove this specificity translates to a clinical advantage over broader dendritic cell or lymph node targeting approaches.

More companies in Drug Delivery & Formulation →More companies in Austria →